% | $
Quotes you view appear here for quick access.

Amedisys Inc. Message Board

cabogordon 12 posts  |  Last Activity: Apr 6, 2015 3:36 PM Member since: Feb 2, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    the daily chart looks horable

    by cabogordon Apr 6, 2015 3:34 PM
    cabogordon cabogordon Apr 6, 2015 3:36 PM Flag

    or 200ma with a BIO washout 5.49

  • yet with any BIO gd news could change it in a nano sec. yet, without news ZIOP heads lower. perhaps to 8.72

  • Reply to


    by cabogordon Mar 25, 2015 10:23 AM
    cabogordon cabogordon Mar 25, 2015 11:27 AM Flag

    regarding LOI and contracts all based on approval.. nothing more. stay objective brother... I´ve been long since the teens... took some off but still holding some through binary event. remove fear...

  • Reply to


    by cabogordon Mar 25, 2015 10:23 AM
    cabogordon cabogordon Mar 25, 2015 11:25 AM Flag

    I said well written . Dr. Ogut is leading GT specialists on the plannet. read his blog. and please remember character counts when communicating with people. blessings to you whether long or short. god speed.

  • Reply to


    by cabogordon Mar 25, 2015 10:23 AM
    cabogordon cabogordon Mar 25, 2015 10:48 AM Flag

    This is a very well written article. Whether long or short its information from a very respected doctor in the space.

  • Reply to


    by cabogordon Mar 25, 2015 10:23 AM
    cabogordon cabogordon Mar 25, 2015 10:40 AM Flag

    In experiments with larger animals, however, you don't see the same effect. You don't see the overexpression of the (SERCA2a) protein in the heart tissue," Ogut said. Ogut has no affiliation with Celladon and has no investment position in the company.

    Measuring SERCA2a levels in heart-failure patients would be the most definitive way to resolve the question about whether the Mydicar gene therapy does what it's designed to do. Unfortunately, this analysis requires removing a small sample of heart tissue from patients, which can be done only if the patient dies or undergoes invasive cardiac surgery.

    In the 2014 published study of CUPID-1 follow-up, researchers were able to obtain biopsies of cardiac tissue from 11 patients. In three of four patients infused with the high dose of Mydicar, persistent presence of the transferred gene was found. Five patients treated with the low and middle dose of Mydicar showed no presence of the transplanted gene, neither did two placebo patients.

  • cabogordon by cabogordon Mar 25, 2015 10:23 AM Flag

    Celladon skeptics, including investors shorting the stock, believe otherwise. Although it hit the primary efficacy goal, the CUPID-I was not entirely clean. Nine heart-failure patients were enrolled in the high-dose Mydicar arm versus 14 patients on a placebo. The small number of patients raises the risk that the benefit observed is an outlier that won't be replicated in the much larger CUPID-2 study.

    This risk is amplified by the relatively poor performance of heart-failure patients treated with low and middle doses of Mydicar in CUPID-1. On some efficacy measures, patients treated with the middle dose of Mydicar performed worse than a placebo.

    The absence of a consistent dose response in CUPID-1 is worrisome because higher numbers of re-engineered viral particles infused into patients should lead to more healthy, SERCA2a-producing genes taken up inside the cells of the heart muscle. Data on whether Mydicar can actually lead to successful replacement of diseased genes and produce higher levels of SERCA2a protein are unclear.

    "When experiments are run in small animals like mice and rats, the gene therapy works well. The re-engineered virus makes its way into the heart tissue and the [SERCA2a] protein is over-expressed," says Ozgur Ogut, who until late last year was the co-director of the Cardiac Muscle Contractility Laboratory at the Mayo Clinic in Rochester, Minn.

  • The unbinding of data and analysis is done by the FDA not CLDN MGMT. The results are provided in a letter called a CRO. The announcement today is based on approval from the FDA.

  • cabogordon by cabogordon Mar 24, 2015 3:52 PM Flag

    Is doing you a service by highlighting the inherent risk in any major trial. Instead of blasting him you should thank him, Its called objectivity. Its should be a step in everyone investors due diligence otherwise your just drinking the cool aide and following the tea leaves. Its very possible that CLDN hits a homerun and gets permission to get to market yet why not understand the other side of the opportunity. Blessings everyone and good luck on whatever side of the trade you sit...

  • Reply to


    by esteejp Mar 16, 2015 6:25 PM
    cabogordon cabogordon Mar 16, 2015 7:10 PM Flag

    FYI: its a phase 2 FDA event... lol !

  • Reply to

    Nice and quiet

    by allthewayhome1 Mar 2, 2015 7:34 PM
    cabogordon cabogordon Mar 2, 2015 10:15 PM Flag

    everyone is on stocktwits

  • cabogordon by cabogordon Mar 1, 2015 10:04 PM Flag

    things could get parabolic with a float of 12mm and first in man GT phase 2 FDA event with breakthrough status !! hold on to your shares.....

31.83+0.16(+0.51%)May 28 4:00 PMEDT